Phase 2 N=40 A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) — 255 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=138 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
Phase 2 N=448 A Study in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Dose-Response Relationship Measured by the Percentage of Participants With American College of Rheumatology (ACR) 20 Response in bDMARD-Naive Population — 34.1; 46.2…
Phase 2 N=18 Corticosteroids in Postoperative Critically Ill Neonates With Low Cardiac Output Syndrome With Congenital Heart Disease
Cardiac Output, Low
Primary: Blood Pressure. — 6; 5.89 mmHg
Phase 2 N=99 Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
Advanced Breast Cancer
Primary: Number of Participants With Disease Progression (PD) or Death — 35; 40 participants
Phase 2 N=265 Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants
Phase 2 N=42 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma
Liposarcoma · Surgically Unresectable Liposarcoma · Metastatic Liposarcoma
Primary: 12-week Progression Free Rate — 68.29 percentage of participants
Phase 2 N=65 Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
Chemotherapy-Induced Nausea and Vomiting
Primary: Percentage of Participants With Complete Response of Acute and Delayed Chemotherapy Induced Nausea and Vomiting — 29.6; 46.3; 24.1 percentage of participants
Phase 2 N=26 Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Refractory Multiple Myeloma
Primary: Dose-limiting Toxicity (DLT) (Phase I) — 0; 0; 0; 0 participants
Phase 2 N=121 Phase II ABT-888 With Cyclophosphamide
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants
Phase 2 N=105 Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy
Cancer · Influenza Viral Infections
Primary: The Geometric Mean Titer (GMT) of High-dose Influenza Vaccine vs the Standard Trivalent Influenza Vaccine in Adult Subjects on Chemotherapy Who Are Less Than 65 Years…
Phase 2 N=8 Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Efficacy — 372 MFI
Phase 2 N=38 CLOTBUST Hands-Free: A Phase I/II Pilot Safety Trial
Stroke
Primary: Number of Participants in Phase I Group With Blood-brain-barrier Disruption (BBB) as Measured by MRI of the Brain — 0 participants
Phase 2 N=396 Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival (PFS) — 19.4; 5.7 months — p=<0.0001
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants